LOGIN  |  REGISTER
Assertio
Amneal Pharmaceuticals

Acutus Medical to Present at the 43rd Annual Canaccord Growth Conference

July 27, 2023 | Last Trade: US$0.001 0.00 0.00

CARLSBAD, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 43rd Annual Canaccord Growth Conference on Thursday, August 10, 2023 at 9:30 a.m. Eastern Time at the InterContinental Boston Hotel in Boston, MA.

A live webcast of the presentation may be accessed by visiting ir.acutusmedical.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days.

About Acutus Medical, Inc.

Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

Investor Contact
Caroline Corner
ICR Westwicke
D: 415-202-5678
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact
Rhiannon Pickus
442-232-6094
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page